Does surgical site infection influence neurological outcome and survival in patients undergoing surgery for metastatic spinal cord compression? by Quraishi, N. A. et al.
Vol.:(0123456789) 
European Spine Journal 
https://doi.org/10.1007/s00586-018-5797-4
ORIGINAL ARTICLE
Does surgical site infection influence neurological outcome 
and survival in patients undergoing surgery for metastatic spinal cord 
compression?
N. A. Quraishi1  · M. S. Ahmed1 · G. Arealis1 · B. M. Boszczyk1 · K. L. Edwards2
Received: 31 December 2017 / Revised: 23 September 2018 / Accepted: 14 October 2018 
© The Author(s) 2018
Abstract
Purpose Most of the literature on infection after surgery for spinal metastases focuses on incidence and risk factors for 
surgical site infection (SSI). To the best of our knowledge, there is no report on the influence of infection on neurological 
outcome and survival in patients undergoing emergent surgery for metastatic spinal cord compression (MSCC).
Methods Our aim was to establish if SSIs adversely affected the neurological outcome and survival in patients with MSCC. 
We reviewed 318 consecutive patients admitted for surgical intervention for MSCC from October 2005 to October 2012. 
Morbidity (neurological outcome, length of hospital stay and additional procedures) and survival rates were analysed.
Results During this study period, the incidence of infection was 29/318 (9.1%). The median length of stay in hospital in the 
infected group was 25 days compared to 13 days in the non-infected group (p = 0.001). Twenty out of the 29 (69%) infected 
patients underwent an additional procedure (29 procedures in total) compared to 9/289 (3%) non-infected patients (p = 0.001). 
There was no statistical difference between the two groups with regard to neurological outcome (p = 0.37) but the survival 
rate was statistically different between the two groups [infected group: median survival 131 days (19–1558) vs. non-infected 
group: 258 days (5–2696; p = 0.03)].
Conclusion Surgical site infection increased the morbidity with considerably longer hospital stay and requirement for addi-
tional procedures. Although there was no difference in neurological outcome, the infected group of patients had a significantly 
shorter survival.
Graphical abstract These slides can be retrieved under Electronic Supplementary Material.
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Take Home Messages
1. The occurrence of surgical site infection increases the morbidity 
following surgery for MSCC with significantly longer in-patient 
stay, more procedures and shorter survival. 
2. However, the neurological outcome is not adversely affected by the 
occurrence of an infection.
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Introduction
The spine is the most common site of metastases in the skel-
etal system. It is estimated that 10% of patients with cancer 
present initially with spinal metastases. The most common 
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symptoms of MSCC are pain, radiculopathy, myelopathy or 
autonomic dysfunction [1]. The main goal of the surgical 
treatment of the MSCC is to maintain/restore mechanical 
and neurological function. However, the complication rate 
remains relatively high with surgical site infection (SSI) 
after surgery for spinal tumours to be between 0.9 and 38% 
depending on the type of procedure, patient population and 
pre-operative diagnosis [2, 3].
Surgical site infection after spinal surgery is particularly 
distressing with risk of spread of infection to the central nerv-
ous system, chronic pain, deformity, paralysis and even death 
[2]. It is more of a concern when treating MSCC as there is 
higher risk of infection compared to non-tumour spinal sur-
gery [4, 5]. This is likely due to the association of patients 
with spinal tumours having multiple comorbidities, complex 
surgical procedures with instrumentation, adjuvant treat-
ments with radiotherapy, chemotherapy and steroids [2, 6, 7].
Most of the literature on infection after spinal metastases 
focuses on the incidence and risk factors for SSI [8–10]. 
With the improvement in surgical techniques and anaesthetic 
management, patients who are at a higher risk for surgical 
site infections are increasingly being considered for surgery. 
Hence it is imperative to know whether infection poses any 
risk to the neurological outcome and survival in patients 
with MSCC. To the best of our knowledge, there is no report 
in the current literature on the influence of infection on neu-
rological outcome and survival in these patients. The objec-
tive of our study was to analyse the effect of surgical site 
infection on the morbidity including neurological outcome 
and survival in patients with MSCC.
Methods
We performed a retrospective study of prospectively collected 
data of 318 consecutive patients who were admitted for spi-
nal surgery for MSCC between October 2005 and October 
2012. All patients who were surgically treated for MSCC 
with a known or unknown primary tumour were included 
in the study. Exclusion criteria included patients treated by 
radiotherapy alone, patients having a cement augmentation 
procedure without decompression and patients who had 
undergone previous surgery for spinal metastasis. The infor-
mation recorded for each patient included demographic and 
tumour data—age, gender, site and type of primary tumour, 
revised Tokuhashi score [11]; surgical data—site of MSCC 
and type of surgical procedure; outcome data—complica-
tions (especially infection), requirement for further surgery, 
length of hospital stay, change in neurological outcome (Fran-
kel score as recorded in medical notes pre-operatively, post-
operatively and at final follow-up or death) and survival. All 
patients received peri-operative antibiotics to cover commonly 
encountered organism as per our Trust recommendations: a 
single dose of flucloxacillin 1 g IV + IV Gentamicin (< 70 kg, 
120 mg; > 70 kg, 160 mg) with a re-dose of flucloxacil-
lin 1 g IV at 4 h if operation lasts longer than 4 h or blood 
loss > 1500 ml. Flucloxacillin is repeated at 12 and 24 h 
post-operatively where instrumentation is used. Teicoplanin 
400 mg IV is used if allergic to Penicillin. Research approval 
was not required as this study was conducted for ‘service 
evaluation’ as per our Hospitals’ guidelines.
Statistical analysis
Statistical analysis was performed using SPSS 17.0 version 
software (Statistical Package for Social Sciences, SPSS 
Inc.). Student’s t test was used to analyse the statistical sig-
nificance. Survival data were computed using Kaplan–Meier 
product limit method, and the survival curves were drawn 
for each group. Log rank Mantel–Cox test was used to show 




The incidence of infection was 29/318 (9.1%) during the 
8-year study period. There was no statistical difference in the 
general demographic data, mean revised Tokuhashi score, 
albumin levels or adjuvant treatments between the infected 
versus non-infected groups (Table 1).
The distribution of primary tumour type was also similar 
between the two groups (Table 2). There was no significant 
difference in the most common primary tumours. The only 
significant difference between the infected and non-infected 
groups was in the number of unknown primary (greater in 
infected group, p = 0.01) and the ‘other’ tumours (more in 
the non-infected group, p = 0.03).
There was also a similar distribution of the site of MSCC 
in the two groups (Fig. 1)—the majority of these were in the 
thoraco-lumbar region 24/29 (83%) in the infected group 
versus 243/290 (84%) in non-infected group.
Surgical data
In the infected group, all patients except 1 had instrumented 
stabilisation as well as a decompression procedure. In these 
29 patients, all patients had a posterior approach except 1 
who had an anterior approach only. In 18/29 (62%), Staph-
ylococcus aureus was isolated, of which one patient had 
MRSA, 2/29 (6.9%) pseudomonas, 9/29 (31%) mixed gram-
negative organisms. Appropriate antibiotics were used as per 
the sensitivity assay. The infection was deep to the fascia in 
19/29 (65%) and superficial to the fascia in 10/29 (35%).
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In the non-infected group, 272/289 (95%) patients had 
decompression and instrumented stabilisation. The major-
ity again had posterior approaches only (236/289 82%), 
32 (11%) had an anterior approach only and 21 (7%) had 
combined approaches.
Outcome data
The median length of stay was 25 (3–88) days in the 
infected group and 13 (1–181) days in the non-infected 
group, which was statistically significant (p = 0.001). Most 
patients with an infected wound required additional proce-
dures (20/29, 69%) in the form of debridement (Table 3). 
Five patients had to undergo subsequent surgery for non-
resolving infection, and two patients had three surgeries for 
the same. In total, 29 additional procedures were performed 
in this infected group. Vacuum assisted closure dressing 
(VAC dressing, KCI Medical, UK) was used in one patient 
due to extensive skin loss. All other complications are 
shown in Table 4—in the non-infected group, nine patients 
had revision surgery for metalwork failure/tumour recur-
rence and two due to adjacent vertebral body level fracture.
There was no difference in the neurological outcome 
between the groups with most patients remaining the same 
or improving by one Frankel grade—28/29 (96%) in the 
infected group versus 248/289 (86%) in the non-infected 
group (p = 0.37; Tables 5, 6).
The Kaplan–Meier survival curve is shown in Fig. 2. The 
median survival time for the infected group was 131 days 
(19–1558) and 258 days (5–2696) for the non-infected 
group (p = 0.031). The overall survival was 246  days 
(5–2696)—there was 1 death caused directly due to sepsis 
and in the non-infected group there were 3 deaths due to 
pulmonary emboli in the immediate post-operative period. 
Using the Kaplan–Meier method, the survival plot was cre-
ated, and further statistical analysis with the log rank (Man-
tel–Cox) method showed significant difference between the 
groups (p = 0.015). Overall 43.5% survived at final follow-
up (infected group: 28% vs. non-infected 45.5%).
Discussion
This retrospective study is perhaps the first to directly 
study the link between infection in patients undergo-
ing emergent surgery for MSCC with further morbidity 
Table 1  Demographic profile and revised Tokuhashi score
Total (n = 318) Infected (n = 29) Non-infected (n = 289) p value
Mean age (years) 62.5 (± 13) 60 (± 10) 63 (± 14) 0.09
Gender M:F 3:2 1:1 3:2 0.39
Revised Tokuhashi score (mean) 9 (± 4) 8.2 (± 3.8) 9 (± 4) 0.85
Diabetes 5 1 4 N/A
Mean albumin level 27 (14–44) 24 (17–32) 29 (14–44) 0.13
Pre-op radiotherapy 40 (14%) 2 (10%) 38 (13%) 0.38
Pre-op chemotherapy 90 (28%) 11 (38%) 79 (27%)
Pre-op chemotherapy and radiotherapy 33 (10%) 4 (14%) 29 (10%)
Table 2  Type of primary tumour
Primary tumour Infected (n = 29) Non-infected 
(n = 289)
p value
Breast 7 (24%) 35 (12%) 0.07
Lungs 4 (14%) 22 (8%) 0.24
Kidney 2 (7%) 40 (14%) 0.29
Prostate 5 (17%)  41 (14%) 0.65
Genitourinary 4 (14%) 32 (11%) 0.66
Gastrointestinal 2 (7%) 33 (11%) 0.46
Haematological 3 (10%) 47 (16%) 0.41
Unknown primary 6 (21%) 11 (4%) 0.01
Endocrine 0 5 (1.7%) 0.48
Soft tissue 0 18 (6%) 0.17















Fig. 1  Levels affected with MSCC in both groups (%)
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and mortality. During our 8-year study period, our inci-
dence of infection following surgery for MSCC was 9.1% 
(29/318). These patients had significantly longer hospital 
stay (median 25 days vs. 13 days, p = 0.001) and under-
went more procedures (29 in total). Although their neuro-
logical outcome was comparable to non-infected patients, 
the infected group of patients had a significantly shorter 
survival (median 131 days vs. 258 days, p = 0.031).
Surgical site infection after spinal surgery can potentially 
be devastating [2], and thus, prevention and early treatment 
are important strategies. Whilst the management of SSI has 
vastly improved over the years, infection rates for spinal 
tumours have remained at a higher level when compared to 
other spinal surgical procedures [2, 4, 5]. Several studies on 
infection after surgery for spinal tumours have focussed on 
risk factors and this discussion is beyond our paper [2, 3, 8]. 
Diabetes, obesity, malnutrition especially pre-operative pro-
tein depletion, smoking, alcohol use are patient-related risk 
factors. The risk factors that are surgeon related include peri-
operative use of steroids, length of procedure, extent of surgi-
cal procedure and the need for complex plastic closure. Omeis 
et al. [2] in their univariate analysis also found pre-operative 
radiotherapy to be a significant risk factor for SSIs, which is 
in agreement with others [6]. More recently, Kumar and col-
leagues, 2015, studied 95 patients finding quite a high risk of 
infection at 17.9%. They further reported that levels of surgery 
(seven or more) significantly increased the risk of infection in 
patients undergoing surgery for spinal metastases [5].
Quraishi et al. [12] conducted a study of 289 patients 
who underwent urgent surgery for spinal metastasis. These 
authors found a modest re-operation rate (31/289; 10.7%)—
most of these were for surgical site infection (13/31; 42%), 
failure of instrumentation (9/31; 26%) and local recurrence 
(5/31; 16%). They concluded that patients with metastatic 
disease could benefit from revision surgery with compara-
ble median survival rates (single surgery group: 250 days 
(range 5–2597 days) and revision group: 215 days (range 
9–1352 days) but relatively worse neurologic outcome (20 
patients (8%) from the single surgery group and 7 (23%) 
from the revision group were worse off neurologically). 
This study did not look at patients separately with an infec-
tion. Further, only SSI necessitating revision surgery was 
reported. Our present study found an overall infection rate 
of 29/318 (9.1%), and 20 of these required an additional 
surgical procedure.
These patients invariably have a short(er) survival due to 
the nature of their condition. An earlier study from our unit 
showed an average of 45.6-weeks survival in 70 patients 
with spinal metastases [13]. Survival rate in our study over-
all was 43.5% at 1 year and this is consistent with the other 
studies, though generally, other reports have not studied the 
influence of infection on outcome [14].
Survival rate though heavily depends on several factors—
the primary site of tumour, systemic metastases and the 
presence of pathological fracture amongst others. It is also 
Table 3  Length of stay and 
re-operation rates Infected (n = 29) Non-infected (n = 289) p value
Length of stay (median no. of days) 25 (3–88) 13 (1–181) 0.001
Re-operations 20/29 (69%) 10/289 (3.4%)




Table 4  Other complications in both groups
Infected (n = 29) Non-infected (n = 290)
Neurological deficit 2 8
Pulmonary embolism 0 4
Pulmonary oedema 1 6
Respiratory tract infection 1 4




Recurrence of tumour 1 3
Adjacent level fracture 0 2
Total 5/29 (17%) 35/289 (12%)
Table 5  Frankel grade pre-op and post-op in the infected and non-
infected patients
Frankel grade Infected Non-infected
Pre-op Post-op Pre-op Post-op
A 1 2 8 6
B 2 2 6 7
C 5 4 52 51
D 18 14 147 144
E 3 7 76 81
Table 6  Change in neurological status in the infected and non-
infected patients
Change in neurology Infected (n = 29) Non-infected (n = 289)
Improved 13% (4/29) 21% (62/289)
No change 82% (24/29) 65% (186/289)
Deteriorated 3% (1/29) 14% (41/289)
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agreed that the prognosis with myeloma, lymphoma, prostate 
and breast carcinoma is better than that of pulmonary, gastric 
and adenocarcinoma of unknown origin. However, there was 
no significant difference in the revised Tokuhashi score in 
our groups. So, if this score is believed to offer reasonable 
consistency between predicted and actual survival [15], then 
it can be assumed that these two groups were indeed well 
matched in terms of their prognostic scoring. Lei et al. [16] 
have attempted to validate a pre-operative scoring system 
for survival and functional outcome of lung cancer patients 
with MSCC after posterior decompression surgery. Perhaps 
not surprisingly, they found those with shorter survival (life 
expectancy < 3 months) and poor functional outcome to be 
best treated with radiotherapy and palliative care.
The influence of surgery on health-related quality of life 
(HRQoL) has become even more important over the last 
few years [17, 18], especially considering that metastatic 
spinal lesions treated with surgery have the highest mean 
cost among all oncological musculo-skeletal issues [19].
Fehlings et al. [17], in a prospective North American 
multi-centre study of 142 patients with single symptomatic 
MSCC, found that surgery, as an adjunct to radiation and 
chemotherapy, provided immediate and sustained improve-
ment in pain, neurological, functional and HRQoL outcomes 
with acceptable risks in patients who have at least a 3-month 
survival prognosis.
The Global Spine Study Group, in a large prospective 
multi-centre cohort study of over 900 patients, showed sus-
tained improvements in EQ-5D and pain scores over 2 years 
[18]; with the extreme increase in the incidence of cancer in 
China, this country in particular offers the opportunity for a 
national registry [19] to enhance patient care.
In an extensive systematic review conducted by Bakar 
et al. [20], the authors found that the most commonly cited 
complication from decompression surgery for spinal metas-
tases was wound infection or dehiscence (22 studies), which 
occurred in 2.5–16% of patients. The length of construct 
(generally fixation two levels above and two levels below the 
site of cord compression) and duration of surgery are also 
useful considerations for the development of infection which 
we have not reported. But our comparatively lower infection 
rate to Kumar’s series of 17.9% [5] may be due to smaller 
length of constructs that we utilised. Our study is perhaps 
novel in the examination of infection and its effect on neuro-
logical outcome, morbidity and mortality. Furthermore, we 
focus entirely on patients undergoing emergent surgery for 
cord compression caused by spinal metastases. It is however 
a retrospective analysis, be it, in a large number of patients.
Fig. 2  Kaplan–Meier survival 
curve (green line = infected 
group, blue line = non-infected 
group)
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Conclusion
The occurrence of surgical site infection increases the mor-
bidity following surgery for MSCC with significantly longer 
in-patient stay, more procedures and shorter survival. How-
ever, the neurological outcome is not adversely affected by 
the occurrence of an infection.
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